Likewise, Nardi et al. suggested that the activation of the PI3K pathway may contribute to tumorigenesis in a subset of MCC and that screening for PIK3CA mutations could help identify patients who might benefit from PI3K pathway inhibitors [51]. The gene discussed is PIK3CA; the disease is Merkel cell skin cancer.